Myeloid cell nuclear differentiation antigen (MNDA)

Myeloid cell nuclear differentiation antigen (MNDA) is a nuclear protein expressed mainly in cells of the granulocyte–monocyte lineage and a subset of B lymphocytes, notably those of the marginal zone[1][3][4][5]. MNDA belongs to the PYHIN protein family, characterized by pyrin and HIN-200 domains, and functions mainly as a transcription factor in myeloid cells[2][5][6]. It is a key regulator of gene activation in response to interferons, especially promoting the induction of the IRF7 transcription factor, which is critical for type I interferon (IFNα) production in monocytes[5][6]. MNDA controls the transcription of genes regulating apoptosis (such as MCL1 and BCL2), thus playing an important role in programmed cell death[5]. Clinically, MNDA is highly expressed in marginal zone lymphomas and is exploited as a diagnostic and prognostic marker in hematolymphoid neoplasms[4][5]. Abnormal MNDA expression correlates with altered immune and inflammatory responses, emphasizing its importance in infection control, inflammation, and immune pathologies[5][6]. No specific MNDA-targeted therapies are currently known; rather, its clinical relevance is mainly as a biomarker and as a regulatory protein in immunity, with implications for immunomodulation and disease progression.

Other names

Myeloid nuclear differentiation antigenN-GeneInterferon-inducible protein MNDA

Not classically targeted by drugs, but mechanisms could involve modulation of transcription and apoptosis in myeloid cells, disruption of IFNα induction pathways, or inhibition of viral replication by interfering with transcription factors (such as Sp1)